|Tested species reactivity||Bovine, Human, Mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide within the N-terminal region (residues 1-100) of human TREK 1.|
|Purification||Antigen affinity chromatography|
|Storage buffer||tris glycine with 0.15M NaCl|
|Contains||0.05% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Western Blot (WB)||1:1000|
This antibody is 88% homologous to rat. It is not recommended for ICC/IF or Immunohistochemistry applications.
TREK-1 is a two-pore-domain background potassium channel expressed throughout the central nervous system. It is opened by polyunsaturated fatty acids and lysophospholipids. As well, it is regulated by various neurotransmitters. It has been shown that alterations in the functioning, regulation, or both of the TREK-1 channel may alter mood. TREK-1 is also activated by volatile anesthetics and has been suggested to be an important target in the action of these drugs. Therefore, this particular K+ channel emerges as a potential innovative target for developing new therapeutic agents for anesthesiology and neurology, such as antidepressants.
K2P2.1 potassium channel; Kcnk2 antibo; outward rectifying potassium channel protein TREK-1; potassium channel subfamily K member 2; potassium channel subfamily k member 2 variant 1; potassium channel subfamily k member 2 variant 2; Potassium channel, subfamily K, member 2 antibody; potassium channel, two pore domain subfamily K, member 2; potassium inwardly-rectifying channel, subfamily K, member 2; tandem-pore-domain potassium channel TREK-1; TREK-1 K(+) channel subunit; Twik-Related K+ Channel 1 antibody; TWIK-related potassium channel 1; two pore domain potassium channel TREK-1; two pore potassium channel TPKC1; Two-pore domain potassium channel TREK-1 antibody; two-pore potassium channel 1
A430027H14Rik; AI848635; BOS_16115; hTREK-1c; hTREK-1e; K2p2.1; KCNK2; TPKC1; TREK; TREK-1; TREK1